Janney Montgomery Scott’s Amedisys AMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-17,592
Closed -$1.61M 2557
2023
Q2
$1.61M Buy
+17,592
New +$1.44M 0.01% 1180
2023
Q1
Sell
-12,141
Closed -$1.01M 2491
2022
Q4
$1.01M Sell
12,141
-2,149
-15% -$194K ﹤0.01% 1371
2022
Q3
$1.38M Buy
+14,290
New +$1.7M 0.01% 1157
2021
Q1
Sell
-8,098
Closed -$2.38M 2189
2020
Q4
$2.38M Buy
8,098
+1,191
+17% +$305K 0.01% 802
2020
Q3
$1.63M Buy
6,907
+952
+16% +$216K 0.01% 876
2020
Q2
$1.18M Buy
5,955
+1,375
+30% +$256K 0.01% 970
2020
Q1
$841K Sell
4,580
-4,214
-48% -$750K 0.01% 994
2019
Q4
$1.47M Sell
8,794
-438
-5% -$65.1K 0.01% 908
2019
Q3
$1.21M Buy
9,232
+349
+4% +$45.4K 0.01% 951
2019
Q2
$1.08M Buy
8,883
+1,807
+26% +$214K 0.01% 1010
2019
Q1
$872K Buy
7,076
+240
+4% +$30.1K 0.01% 1100
2018
Q4
$801K Sell
6,836
-5,580
-45% -$658K 0.01% 1044
2018
Q3
$1.55M Buy
12,416
+2,842
+30% +$314K 0.01% 803
2018
Q2
$818K Buy
+9,574
New +$703K 0.01% 1095
2013
Q3
Sell
-18,404
Closed -$214K 1898
2013
Q2
$214K Buy
+18,404
New +$211K 0.02% 664

Other funds holding AMED

Janney Montgomery Scott's AMED Position: Q3 2023 in Review

Janney Montgomery Scott sold out of Amedisys (AMED) in Q3 2023, closing a stake of 17,592 shares — an estimated $1.61M sold.

Janney Montgomery Scott first reported a position in AMED in Q2 2013 and held it in 15 quarters. The position peaked at $2.38M in Q4 2020. 286 funds tracked by Wall St. Rank hold AMED as of Q3 2023.

  • Janney Montgomery Scott reported no remaining Amedisys position as of Q3 2023 after selling out during the quarter.
  • Janney Montgomery Scott sold 17,592 Amedisys shares in Q3 2023, an estimated $1.61M.
  • Janney Montgomery Scott first reported a position in Amedisys in Q2 2013 and held it in 15 quarters.
  • Janney Montgomery Scott's Amedisys position peaked at $2.38M in Q4 2020.
  • 286 funds tracked by Wall St. Rank held Amedisys as of Q3 2023.

Based on Janney Montgomery Scott's 13F filing for Q3 2023, filed 8 Nov 2023.